BenevolentAI announces the appointment of biopharma luminary Dr François Nader as Chairman

Dr Nader joins BenevolentAI as it embarks on ambitious growth plans to scale its AI platform, partnerships and drug portfolio.

London, July 8, 2021, BenevolentAI announces the appointment of Dr François Nader as Chairman. 

Dr Nader is an experienced biopharma executive currently serving as Chairman of Talaris, Acceleron Pharma, independent Board Director at Moderna and Alexion and as a senior adviser at Blackstone Life Sciences. Following a distinguished career, Dr Nader's most recent operating role was as President, CEO and Executive Director of NPS Pharma from 2008 to 2015, ultimately engineering its sale to Shire.  

Joanna Shields, CEO, BenevolentAI and Board Director, commented: “Dr François Nader brings a wealth of late-stage, high growth expertise to our Board.  After a momentous year of pipeline progress and continued AI platform validation, we are poised for the next growth stage to deliver new medicines at speed and scale. We welcome François’ vision and commitment to developing a purposeful and category-defining business.”  

Dr François Nader commented: “Benevolent stood out because of its innovative computational R&D platform and focus on mechanism-based drug discovery, with recent milestones reaffirming the value of this approach. I look forward to chairing the company at this pivotal moment in its journey and to working with its experienced Directors and leadership team to unlock the value of Benevolent’s rich drug pipeline and fuel the company’s future growth and success.”

As a 30-year veteran of the biopharma industry, Dr Nader brings broad expertise across drug development, regulatory affairs and commercial to BenevolentAI’s scientific leadership team. Dr Nader earned his French Doctorate in Medicine from St. Joseph University (Lebanon) and his Physician Executive MBA from the University of Tennessee (USA). In 2013 he was recognised as the EY National Life Science Entrepreneur of the Year® and was awarded the Ellis Island Medal of Honor® in 2017. Dr Nader will sit alongside respected industry experts, including recently appointed Non-Executive Director Sir Nigel Shadbolt and BenevolentAI’s Founder and former Chairman, Ken Mulvany, who will stay on as Non-Executive Director. 

Founder Ken Mulvany commented: "I am hugely proud of BenevolentAI’s accomplishments during the last eight years: from its platform to its partnerships and drug pipeline. François brings formidable biopharma experience to our Board and I am confident that he will help move the company towards even greater levels of success.” 

Media inquiries

Rajin Kang 

About BenevolentAI 

BenevolentAI combines advanced AI and machine learning with cutting edge science to decipher complex disease biology, generate novel insights and discover more effective medicines. Our unique computational R&D platform spans every step of the drug discovery process, powering an in-house pipeline of 25+ drug programmes from early discovery towards clinical phases. With several successful collaborations with leading pharmaceutical organisations, we are also the only AI-drug discovery company with a clinically validated approach, discovering a leading repurposed drug candidate for COVID-19. BenevolentAI is headquartered in London with a research facility in Cambridge (UK) and a further office in New York, with a team of over 300 world-leading scientists and technologists progressing its mission to reinvent drug discovery and advance life-changing drugs through to the clinic.

More Posts

You Might Also Like

AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021
Product design in AI-drug discovery: how to design products for and with scientific users
User interfaces can help drug discovery scientists to leverage insights from AI algorithms. Yet, designing products to enable scientific discovery is complex. Our product designer, Róża explores the key steps in her design process.
Jul 6, 2021
Baricitinib, first identified by BenevolentAI as a COVID-19 treatment, is granted emergency use in India in response to its escalating crisis
Baricitinib - first identified by BenevolentAI as a potential COVID-19 treatment - is accelerated for use in hospitalised patients in India following a continued surge in cases and fatalities.
May 5, 2021
A New Era in Target Discovery: Collaborating with AstraZeneca on CKD and IPF
Finding the right target underpins the success of the entire drug discovery process. Learn how BenevolentAI’s collaboration with AstraZeneca is making a difference in CKD and IPF.
Apr 23, 2021
Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population
Apr 8, 2021
BenevolentAI named as one of Fierce Medtech’s Fierce 15 of 2020
BenevolentAI was selected as one of the most promising private companies in the industry by Fierce Medtech in its Fierce 15 2020 list.
Mar 8, 2021